ERBB2 and neoplasm: IHC staining analysis revealed that the expression of DPAGT1 was markedly increased in the pretherapeutic HER2+ breast tumors from patients who had recurrence within 5 years after surgery compared with that of patients without tumor recurrence (Figure 1I).